

World Journal of *Clinical Cases*

World J Clin Cases 2022 December 16; 10(35): 12804-13147



EVIDENCE REVIEW

- 12804 Principle and progress of radical treatment for locally advanced esophageal squamous cell carcinoma
Zhang XF, Liu PY, Zhang SJ, Zhao KL, Zhao WX

REVIEW

- 12812 Minimally invasive techniques in benign and malignant adrenal tumors
Dogrul AB, Cennet O, Dincer AH
- 12822 Planning issues on linac-based stereotactic radiotherapy
Huang YY, Yang J, Liu YB

MINIREVIEWS

- 12837 Hepatitis of unknown etiology in children: Current evidence and association
Zhong R, Yi F, Xiang F, Qiu YF, Zhu L, Zou YH, Wang W, Zhang Q
- 12844 Anatomical basis for pancreas transplantation *via* isolated splenic artery perfusion: A literature review
Dmitriev I, Oganesyan M, Popova A, Orlov E, Sinelnikov M, Zharikov Y
- 12854 Antenatal imaging: A pictorial review
Ece B, Aydın S, Kantarci M
- 12875 Real role of growth factor receptor-binding protein 10: Linking lipid metabolism to diabetes cardiovascular complications
Yang Y, Yao HJ, Lin WJ, Huang SC, Li XD, He FZ

ORIGINAL ARTICLE**Retrospective Study**

- 12880 Radiological and clinical outcomes of midline lumbar fusion on sagittal lumbar-pelvic parameters for degenerative lumbar diseases
Wang YT, Li BX, Wang SJ, Li CD, Sun HL
- 12890 Clinical features of elderly patients with COVID-19 in Wuhan, China
Wei S, Chen G, Ouyang XC, Hong YC, Pan YH

Observational Study

- 12899 Do inflammatory bowel disease patient preferences from treatment outcomes differ by ethnicity and gender? A cross-sectional observational study
Naftali T, Richter V, Mari A, Khoury T, Shirin H, Broide E

- 12909** Lipoprotein (a) variability is associated with mean follow-up C-reactive protein in patients with coronary artery disease following percutaneous coronary intervention
Zhang SS, Hu WY, Li YJ, Yu J, Sang S, Alsalman ZM, Xie DQ
- 12920** Efficacy evaluation of neuroendoscopy *vs* burr hole drainage in the treatment of chronic subdural hematoma: An observational study
Wang XJ, Yin YH, Wang ZF, Zhang Y, Sun C, Cui ZM
- 12928** Optimal approach for total endoscopic discectomy and its effect on lumbar and leg function in patients with disc herniation
Zhang ZH, Du Q, Wu FJ, Liao WB
- 12936** Value of inflammatory mediator profiles and procalcitonin in predicting postoperative infection in patients with hypertensive cerebral hemorrhage
Yin RH, Zhang B, Zhou XH, Cao LP, Li M

SYSTEMATIC REVIEWS

- 12946** *De novo* non-alcoholic fatty liver disease after pancreatectomy: A systematic review
Shah P, Patel V, Ashkar M

META-ANALYSIS

- 12959** Comparative effectiveness of first-line therapies for eradication of antibiotic-resistant *Helicobacter pylori* strains: A network meta-analysis
Zou SP, Cheng Q, Feng CY, Xu C, Sun MH

CASE REPORT

- 12971** Malignant atrophic papulosis: Two case reports
Li ZG, Zhou JM, Li L, Wang XD
- 12980** Endoscopic treatment of urothelial encrusted pyelo-ureteritis disease: A case series
Liu YB, Xiao B, Hu WG, Zhang G, Fu M, Li JX
- 12990** Nearly-complete labial adhesions diagnosed with repetitive cystitis in postmenopausal women: A case report
Kwon H
- 12996** Congenital dysfibrinogenemia misdiagnosed and inappropriately treated as acute fatty liver in pregnancy: A case report and review of literature
Jia Y, Zhang XW, Wu YS, Wang QY, Yang SL
- 13006** Lung squamous cell carcinoma presenting as rare clustered cystic lesions: A case report and review of literature
Shen YY, Jiang J, Zhao J, Song J
- 13015** Management of ductal spasm in a neonate with pulmonary atresia and an intact ventricular septum during cardiac catheterization: A case report
Zhang X, Zhang N, Song HC, Ren YY

- 13022** Symptomatic accessory soleus muscle: A cause for exertional compartment syndrome in a young soldier: A case report
Woo I, Park CH, Yan H, Park JJ
- 13028** Multiple myeloma presenting with amyloid arthropathy as the first manifestation: Two case reports
He C, Ge XP, Zhang XH, Chen P, Li BZ
- 13038** Kawasaki disease without changes in inflammatory biomarkers: A case report
Yamashita K, Kanazawa T, Abe Y, Naruto T, Mori M
- 13044** Atypical Whipple's disease with special endoscopic manifestations: A case report
Chen S, Zhou YC, Si S, Liu HY, Zhang QR, Yin TF, Xie CX, Yao SK, Du SY
- 13052** Acute limb ischemia after minimally invasive cardiac surgery using the ProGlide: A case series
Lee J, Huh U, Song S, Lee CW
- 13058** Genetic changes in refractory relapsed acute myeloid leukemia with *NPM1* mutation: A case report
Wang SL
- 13064** Successful surgical treatment of polybacterial gas gangrene confirmed by metagenomic next-generation sequencing detection: A case report
Lu HY, Gao YB, Qiu XW, Wang Q, Liu CM, Huang XW, Chen HY, Zeng K, Li CX
- 13074** Pulmonary sarcoidosis: A novel sequelae of drug reaction with eosinophilia and systemic symptoms: A case report
Hu YQ, Lv CY, Cui A
- 13081** Hammered silver appearance of the corneal endothelium in Fuchs uveitis syndrome: A case report
Cheng YY, Wang CY, Zheng YF, Ren MY
- 13088** Tracheostomy and venovenous extracorporeal membrane oxygenation for difficult airway patient with carinal melanoma: A case report and literature review
Liu IL, Chou AH, Chiu CH, Cheng YT, Lin HT
- 13099** Surgery combined with antibiotics for thoracic vertebral *Escherichia coli* infection after acupuncture: A case report
Mo YF, Mu ZS, Zhou K, Pan D, Zhan HT, Tang YH
- 13108** Multidisciplinary treatment of a patient with severe immune checkpoint inhibitor-induced colitis: A case report
Lu L, Sha L, Feng Y, Yan L
- 13115** Systemic combined with intravitreal methotrexate for relentless placoid chorioretinitis: A case report
Luo L, Chen WB, Zhao MW, Miao H
- 13122** Response to roxadustat in a patient undergoing long-term dialysis and allergic to erythropoiesis-stimulating agents: A case report
Xu C, Luo DG, Liu ZY, Yang D, Wang DD, Xu YZ, Yang J, Fu B, Qi AR

13129 Liver collision tumor of primary hepatocellular carcinoma and neuroendocrine carcinoma: A rare case report

Jeng KS, Huang CC, Chung CS, Chang CF

13138 Unexpected delayed reversal of rocuronium-induced neuromuscular blockade by sugammadex: A case report and review of literature

Wang HC, Lu CW, Lin TY, Chang YY

LETTER TO THE EDITOR

13146 Immunoglobulin G4 associated autoimmune cholangitis and pancreatitis and nivolumab

Joob B, Wiwanitkit V

ABOUT COVER

Editorial Board Member of *World Journal of Clinical Cases*, Lovenish Bains, FACS, FICS, FRCS, MBBS, MS, Associate Professor, Surgeon, Teacher, Department of Surgery, Maulana Azad Medical College, New Delhi 110002, India. lovenishbains@gmail.com

AIMS AND SCOPE

The primary aim of *World Journal of Clinical Cases* (*WJCC*, *World J Clin Cases*) is to provide scholars and readers from various fields of clinical medicine with a platform to publish high-quality clinical research articles and communicate their research findings online.

WJCC mainly publishes articles reporting research results and findings obtained in the field of clinical medicine and covering a wide range of topics, including case control studies, retrospective cohort studies, retrospective studies, clinical trials studies, observational studies, prospective studies, randomized controlled trials, randomized clinical trials, systematic reviews, meta-analysis, and case reports.

INDEXING/ABSTRACTING

The *WJCC* is now abstracted and indexed in Science Citation Index Expanded (SCIE, also known as SciSearch®), Journal Citation Reports/Science Edition, Current Contents®/Clinical Medicine, PubMed, PubMed Central, Scopus, Reference Citation Analysis, China National Knowledge Infrastructure, China Science and Technology Journal Database, and Superstar Journals Database. The 2022 Edition of Journal Citation Reports® cites the 2021 impact factor (IF) for *WJCC* as 1.534; IF without journal self cites: 1.491; 5-year IF: 1.599; Journal Citation Indicator: 0.28; Ranking: 135 among 172 journals in medicine, general and internal; and Quartile category: Q4. The *WJCC*'s CiteScore for 2021 is 1.2 and Scopus CiteScore rank 2021: General Medicine is 443/826.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: *Hua-Ge Yu*; Production Department Director: *Xiang Li*; Editorial Office Director: *Jin-Lei Wang*.

NAME OF JOURNAL

World Journal of Clinical Cases

ISSN

ISSN 2307-8960 (online)

LAUNCH DATE

April 16, 2013

FREQUENCY

Thrice Monthly

EDITORS-IN-CHIEF

Bao-Gan Peng, Jerzy Tadeusz Chudek, George Kontogeorgos, Maurizio Serati, Ja Hyeon Ku

EDITORIAL BOARD MEMBERS

<https://www.wjgnet.com/2307-8960/editorialboard.htm>

PUBLICATION DATE

December 16, 2022

COPYRIGHT

© 2022 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS

<https://www.wjgnet.com/bpg/gerinfo/204>

GUIDELINES FOR ETHICS DOCUMENTS

<https://www.wjgnet.com/bpg/GerInfo/287>

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH

<https://www.wjgnet.com/bpg/gerinfo/240>

PUBLICATION ETHICS

<https://www.wjgnet.com/bpg/GerInfo/288>

PUBLICATION MISCONDUCT

<https://www.wjgnet.com/bpg/gerinfo/208>

ARTICLE PROCESSING CHARGE

<https://www.wjgnet.com/bpg/gerinfo/242>

STEPS FOR SUBMITTING MANUSCRIPTS

<https://www.wjgnet.com/bpg/GerInfo/239>

ONLINE SUBMISSION

<https://www.f6publishing.com>

Real role of growth factor receptor-binding protein 10: Linking lipid metabolism to diabetes cardiovascular complications

Yang Yang, Hua-Jie Yao, Wei-Jie Lin, Si-Chao Huang, Xiao-Dong Li, Fa-Zhong He

Specialty type: Pharmacology and pharmacy

Provenance and peer review: Invited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review report's scientific quality classification

Grade A (Excellent): 0
Grade B (Very good): 0
Grade C (Good): C
Grade D (Fair): D
Grade E (Poor): 0

P-Reviewer: Dalpatadu KPC, Sri Lanka; Xiao XH, China

Received: September 20, 2022

Peer-review started: September 20, 2022

First decision: October 21, 2022

Revised: November 13, 2022

Accepted: November 17, 2022

Article in press: November 17, 2022

Published online: December 16, 2022



Yang Yang, Wei-Jie Lin, Si-Chao Huang, Department of Pharmacy, Zhuhai People's Hospital (Zhuhai Hospital Affiliated with Jinan University), Zhuhai 519000, Guangdong Province, China

Hua-Jie Yao, College of Life Science and Technology, Wuhan Polytechnic University, Wuhan 430000, Hubei Province, China

Xiao-Dong Li, Fa-Zhong He, Department of Quality Control, Zhuhai People's Hospital (Zhuhai Hospital Affiliated with Jinan University), Zhuhai 519000, Guangdong Province, China

Corresponding author: Fa-Zhong He, PhD, Pharmacist, Department of Quality Control, Zhuhai People's Hospital (Zhuhai Hospital Affiliated with Jinan University), No. 79 Kangning Road, Zhuhai 519000, Guangdong Province, China. fazhong2006@ext.jnu.edu.cn

Abstract

Cardiovascular complications of patients with type 2 diabetes mellitus (T2DM) threaten the health and life of numerous individuals. Recently, growth factor receptor-binding protein 10 (GRB10) was found to play a pivotal role in vascular complications of T2DM, which participates in the regulation of lipid metabolism of T2DM patients. The genetic variation of *GRB10* rs1800504 is closely related to the risk of coronary heart disease in patients with T2DM. The development of GRB10 as a key mediator in the association of lipid metabolism with cardiovascular complications in T2DM is detailed in and may provide new potential concerns for the study of cardiovascular complications in T2DM patients.

Key Words: Type 2 diabetes mellitus; Growth factor receptor-binding protein 10; Vascular complications; Lipid metabolism

©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: Growth factor receptor-binding protein 10 (GRB10) performs a vital role in vascular complications of type 2 diabetes mellitus (T2DM). GRB10 variant may be associated with the blood lipids and then may also related to the risk of coronary heart disease in patients with T2DM. GRB10 is expected to be a potential target for the prevention and treatment of vascular complications in patients with T2DM.

Citation: Yang Y, Yao HJ, Lin WJ, Huang SC, Li XD, He FZ. Real role of growth factor receptor-binding protein 10: Linking lipid metabolism to diabetes cardiovascular complications. *World J Clin Cases* 2022; 10(35): 12875-12879

URL: <https://www.wjgnet.com/2307-8960/full/v10/i35/12875.htm>

DOI: <https://dx.doi.org/10.12998/wjcc.v10.i35.12875>

INTRODUCTION


Growth factor receptor-binding (GRB) proteins belong to a class of multi-structural domain adaptor proteins with various cellular functions. Among all GRB proteins, GRB7, GRB10, and GRB14 have similar overall structure, including an N-terminal proline-rich domain, a central pleckstrin-homologous PH domain, a C-terminal SH2 domain, and a family-specific BPS domain (between PH and SH2 domains)[1-3]. GRB10 is an adaptor protein in the GRB7/GRB10/GRB14 protein family. It has three subtypes, GRB10 α , GRB10 β and GRB10 γ , of which GRB10 γ subtype has the longest amino acid chain in length, while GRB10 α subtype has the shortest amino acid chain in length[4,5]. Molecular biology studies have confirmed that GRB10 can interact with multiple tyrosine kinase receptors and affect a variety of intracellular signaling pathways. In addition, GRB10 plays a key regulatory role in myriad cellular functions such as proliferation, apoptosis and metabolism[6-8]. Besides, Di Paola *et al*[9] found that the minor allele variant of *GRB10* rs4947710 was associated with the low risk of type 2 diabetes mellitus (T2DM) in Caucasian subjects from Italy, while *GRB10* rs2237457 gene variant was related to the development of T2DM in the Amish population. A recent study found the *GRB10* rs1800504 gene variant was associated with coronary heart disease (CHD) susceptibility in T2DM patients. Relative to the TT genotype, the CC + CT genotype may contribute to a significant increase of CHD incidence in T2DM and the mechanism may be achieved by regulating the levels of circulating blood lipids. In vitro experiments further confirmed that GRB10 rs1800504 genetic variation is related to lipid metabolism in hepatocytes[10]. Therefore, this article will focus on the role and mechanism of GRB10 in regulating vascular endothelial function and lipid metabolism, aiming to clarify the important role of GRB10 in the occurrence and development of vascular complications of T2DM.

GRB10 AND T2DM-RELATED CARDIOVASCULAR COMPLICATIONS

Vascular complications of diabetes are the leading reason for death of patients with T2DM, which include macrovascular and microvascular complications (Figure 1). Diabetic macroangiopathy includes cardiovascular disease, cerebrovascular disease and peripheral arterial disease, among which cardiovascular disease is the most common cause of death in diabetic patients[11,12]. One of the major hallmarks of diabetic macrovascular disease is the imbalance of vascular homeostasis caused by dysfunction of endothelial cells and smooth muscle cells, which eventually leads to atherosclerosis and thrombosis[13,14]. Reddy *et al*[15] discovered that GRB10 a critical downstream mediator of miR-504 in vascular smooth muscle cell (VSMC), and miR-504 was closely associated with VSMC dysfunction in mice with T2DM. Furthermore, as a key regulator of angiogenesis, vascular endothelial growth factor (VEGF) is widely known to be involved in the development of numerous angiogenesis-related disorders. Activation of VEGF receptor leads to recruitment of SH2 containing protein, so VEGF stimulation can increase the expression level of GRB10, while the overexpression of GRB10 leads to the increase of VEGFR2 and tyrosine phosphorylation[16,17]. It is revealed that GRB10 might participate in the positive feedback loop of the VEGF signaling pathway. Therefore, GRB10 may be a key gene in the process of VEGF regulating diabetic vascular complications.

GRB10 AND LIPID METABOLISM

Insulin resistance and lipid metabolism disorder are the main causes of T2DM, and they are also crucial factors leading to diabetic vascular complications. Holt *et al*[18] found that GRB10 was highly expressed in tissues involving insulin action and glucose metabolism, such as muscle, pancreas and adipose tissue. Relevant data show that severe obesity (Body mass index > 35 kg/m²) can increase the risk of diabetes and coronary heart disease by about two times[19]. Wang *et al*[20] demonstrated that GRB10 could interact with IGF1R to negatively modulate IGF/IGF1R signaling pathway. IGF1R overexpressed in diabetes, and may lead to insulin resistance by blocking insulin signal transduction. Insulin resistance can result in lipid metabolism disorder and obesity. On the contrary, obesity further aggravates insulin resistance. Obesity leads to heterotopic deposition of fat and insufficient insulin signal transduction, followed by insulin resistance, inhibition of hepatic glycogen synthesis and increase of hepatic gluconeogenesis, which eventually leads to abnormal lipid metabolism in peripheral tissues such as adipocytes[21,22].



DOI: 10.12998/wjcc.v10.i35.12875 Copyright ©The Author(s) 2022.

Figure 1 Growth factor receptor-binding protein 10 is involved in the regulation of cardiovascular complications in patients with type 2 diabetes. GRB10: Growth factor receptor-binding protein 10; mTORC1: Mammalian target of rapamycin complex 1.

Insulin can enhance the intake of FFA by adipocytes and the synthesis of triglycerides[23]. However, insulin resistance leads to the increase of FFA, which in turn promotes the occurrence of atherosclerosis [24]. Moreover, Trayhurn *et al*[25] found that the cytokines [such as tumor necrosis factor- α , interleukin (IL)-1 β , IL-6 and plasminogen activator inhibitor-1] released by adipose tissue of T2DM patients can promote chronic inflammation and thrombosis. About 97% of T2DM patients have dyslipidemia, which is closely related to atherosclerosis[26].

GRB10 is closely related to obesity and participates in lipid metabolism. Studies have shown that specific knock-down of GRB10 in peripheral tissues leads to significant overgrowth of mice[20]. The mutation of GRB 10/14 is also related to obesity and insulin resistance[27]. The silenced GRB10 gene can be reactivated by acute ER stress, and its reactivation plays an important role in the early development of hepatic steatosis[28]. A study by Madon-Simon *et al*[29] found that GRB10 affected the fat ratio, glucose metabolism regulation and lipid storage in the liver. Besides, recent clinical study found that patients with TT genotype of *GRB10* rs1800504 had significantly lower levels of cholesterol and low-density lipoprotein cholesterol than patients with CC + CT genotype. Compared to GRB10-WT, the total cholesterol level was notably reduced in GRB10-Mut of MIHA cells[10]. Cold exposure obviously induced the expression of GRB10 in adipose tissues. In addition, fat-specific knockout of GRB10 inhibits the expression of lipogenic and thermogenic genes, reduces energy consumption, and aggravates diet-induced obesity and insulin resistance[30]. In conclusion, GRB10 plays an important role in lipid metabolism.

The mammalian target of rapamycin complex 1 (mTORC1) signaling pathway is an important regulatory pathway for cell growth and metabolism. The deletion of GRB 10 and the over-activation of mTORC1 lead to the increase of insulin over-expression, thus inhibiting the activation of PI3K/Akt signal pathway mediated by insulin. GRB10 negatively regulates insulin and mTORC1 signals in insulin target cells[31,32]. mTORC1 is highly active in tissues of rodents fed an obese and high-fat diet[33]. In vitro, activation of the mTORC1 signaling pathway has been shown to inhibit lipolysis, stimulate lipogenesis, and promote lipid accumulation in cells[34]. On the other hand, inhibition of mTORC1 promotes triacylglycerol glycolysis and the release of free fatty acids, blocking fat production and impairing the maintenance of adipocytes[35,36]. GRB10 can promote the metabolism of thermogenic brown adipose cells, inhibit lipogenesis, regulate the expression of thermogenic genes and energy consumption by negatively regulating the mTORC1 signaling pathway[30]. Therefore, GRB10 may negatively regulate lipid metabolism by inhibiting mTORC1 pathway, and then participate in the pathogenesis of diabetic vascular complications.

CONCLUSION

T2DM is a major risk factor for cardiovascular disease. In recent years, the therapeutic strategy for

T2DM has shifted from lowering blood glucose to reducing target organ damage and improving clinical outcomes for patients. The management of cardiovascular complications in patients with T2DM is widely respected for improving the quality of life for T2DM patients. Here we discussed that GRB10 is associated with the risk of cardiovascular complications in T2DM patients by affecting lipid metabolism of T2DM patients. Its potential mechanism may be mediated through the VEGF and mTORC1 pathway. However, our conclusion needs to be confirmed by more studies. In summary, GRB10 might be a new potential target for the prevention and therapy of vascular complications in T2DM patients.

FOOTNOTES

Author contributions: Yang Y performed the majority of the writing, prepared the figures; Yao HJ coordinated the writing of the paper; Lin WJ and Huang SC contributed to the design of this work, and performed overall supervision; He FZ and Li XD revised the paper, and make equal contributions; and all authors approved the final manuscript.

Supported by Zhuhai People's Hospital (Zhuhai Hospital Affiliated with Jinan University) Cultivation Project, No. 2009PY-09; National Scientific Foundation of China, No. 81903715.

Conflict-of-interest statement: All authors declare that there are no conflicts of interest.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

Country/Territory of origin: China

ORCID number: Xiao-Dong Li [0000-0002-7851-3776](https://orcid.org/0000-0002-7851-3776); Fa-Zhong He [0000-0001-5750-0135](https://orcid.org/0000-0001-5750-0135).

S-Editor: Wang JL

L-Editor: A

P-Editor: Wang JL

REFERENCES

- Margolis B**, Silvennoinen O, Comoglio F, Roonprapunt C, Skolnik E, Ullrich A, Schlessinger J. High-efficiency expression/cloning of epidermal growth factor-receptor-binding proteins with Src homology 2 domains. *Proc Natl Acad Sci U S A* 1992; **89**: 8894-8898 [PMID: [1409582](https://pubmed.ncbi.nlm.nih.gov/1409582/) DOI: [10.1073/pnas.89.19.8894](https://doi.org/10.1073/pnas.89.19.8894)]
- Frantz JD**, Giorgetti-Peraldi S, Ottinger EA, Shoelson SE. Human GRB-IRbeta/GRB10. Splice variants of an insulin and growth factor receptor-binding protein with PH and SH2 domains. *J Biol Chem* 1997; **272**: 2659-2667 [PMID: [9006901](https://pubmed.ncbi.nlm.nih.gov/9006901/) DOI: [10.1074/jbc.272.5.2659](https://doi.org/10.1074/jbc.272.5.2659)]
- Ooi J**, Yajnik V, Immanuel D, Gordon M, Moskow JJ, Buchberg AM, Margolis B. The cloning of Grb10 reveals a new family of SH2 domain proteins. *Oncogene* 1995; **10**: 1621-1630 [PMID: [7731717](https://pubmed.ncbi.nlm.nih.gov/7731717/)]
- Daly RJ**. The Grb7 family of signalling proteins. *Cell Signal* 1998; **10**: 613-618 [PMID: [9794242](https://pubmed.ncbi.nlm.nih.gov/9794242/) DOI: [10.1016/s0898-6568\(98\)00022-9](https://doi.org/10.1016/s0898-6568(98)00022-9)]
- Dong LQ**, Du H, Porter SG, Kolakowski LF Jr, Lee AV, Mandarino LJ, Fan J, Yee D, Liu F. Cloning, chromosome localization, expression, and characterization of an Src homology 2 and pleckstrin homology domain-containing insulin receptor binding protein hGrb10gamma. *J Biol Chem* 1997; **272**: 29104-29112 [PMID: [9360986](https://pubmed.ncbi.nlm.nih.gov/9360986/) DOI: [10.1074/jbc.272.46.29104](https://doi.org/10.1074/jbc.272.46.29104)]
- Holt LJ**, Siddle K. Grb10 and Grb14: enigmatic regulators of insulin action--and more? *Biochem J* 2005; **388**: 393-406 [PMID: [15901248](https://pubmed.ncbi.nlm.nih.gov/15901248/) DOI: [10.1042/bj20050216](https://doi.org/10.1042/bj20050216)]
- Riedel H**. Grb10 exceeding the boundaries of a common signaling adapter. *Front Biosci* 2004; **9**: 603-618 [PMID: [14766395](https://pubmed.ncbi.nlm.nih.gov/14766395/) DOI: [10.2741/1227](https://doi.org/10.2741/1227)]
- Lim MA**, Riedel H, Liu F. Grb10: more than a simple adaptor protein. *Front Biosci* 2004; **9**: 387-403 [PMID: [14766376](https://pubmed.ncbi.nlm.nih.gov/14766376/) DOI: [10.2741/1226](https://doi.org/10.2741/1226)]
- Di Paola R**, Wojcik J, Succurro E, Marucci A, Chandalia M, Padovano L, Powers C, Merla G, Abate N, Sesti G, Doria A, Trischitta V. GRB10 gene and type 2 diabetes in Whites. *J Intern Med* 2010; **267**: 132-133 [PMID: [19818100](https://pubmed.ncbi.nlm.nih.gov/19818100/) DOI: [10.1111/j.1365-2796.2009.02089.x](https://doi.org/10.1111/j.1365-2796.2009.02089.x)]
- Yang Y**, Qiu W, Meng Q, Liu M, Lin W, Yang H, Wang R, Dong J, Yuan N, Zhou Z, He F. *GRB10* rs1800504 Polymorphism Is Associated With the Risk of Coronary Heart Disease in Patients With Type 2 Diabetes Mellitus. *Front Cardiovasc Med* 2021; **8**: 728976 [PMID: [34651026](https://pubmed.ncbi.nlm.nih.gov/34651026/) DOI: [10.3389/fcvm.2021.728976](https://doi.org/10.3389/fcvm.2021.728976)]
- Dal Canto E**, Ceriello A, Rydén L, Ferrini M, Hansen TB, Schnell O, Standl E, Beulens JW. Diabetes as a cardiovascular risk factor: An overview of global trends of macro and micro vascular complications. *Eur J Prev Cardiol* 2019; **26**: 25-32 [PMID: [31722562](https://pubmed.ncbi.nlm.nih.gov/31722562/) DOI: [10.1177/2047487319878371](https://doi.org/10.1177/2047487319878371)]

- 12 **Einarson TR**, Acs A, Ludwig C, Panton UH. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007-2017. *Cardiovasc Diabetol* 2018; **17**: 83 [PMID: 29884191 DOI: 10.1186/s12933-018-0728-6]
- 13 **Beckman JA**, Paneni F, Cosentino F, Creager MA. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part II. *Eur Heart J* 2013; **34**: 2444-2452 [PMID: 23625211 DOI: 10.1093/eurheartj/eh142]
- 14 **Samuel VT**, Shulman GI. Nonalcoholic Fatty Liver Disease, Insulin Resistance, and Ceramides. *N Engl J Med* 2019; **381**: 1866-1869 [PMID: 31693811 DOI: 10.1056/NEJMcibr1910023]
- 15 **Reddy MA**, Das S, Zhuo C, Jin W, Wang M, Lanting L, Natarajan R. Regulation of Vascular Smooth Muscle Cell Dysfunction Under Diabetic Conditions by miR-504. *Arterioscler Thromb Vasc Biol* 2016; **36**: 864-873 [PMID: 26941017 DOI: 10.1161/ATVBAHA.115.306770]
- 16 **Giorgetti-Peraldi S**, Murdaca J, Mas JC, Van Obberghen E. The adapter protein, Grb10, is a positive regulator of vascular endothelial growth factor signaling. *Oncogene* 2001; **20**: 3959-3968 [PMID: 11494124 DOI: 10.1038/sj.onc.1204520]
- 17 **Murdaca J**, Treins C, Monthouël-Kartmann MN, Pontier-Bres R, Kumar S, Van Obberghen E, Giorgetti-Peraldi S. Grb10 prevents Nedd4-mediated vascular endothelial growth factor receptor-2 degradation. *J Biol Chem* 2004; **279**: 26754-26761 [PMID: 15060076 DOI: 10.1074/jbc.M311802200]
- 18 **Holt LJ**, Brandon AE, Small L, Suryana E, Preston E, Wilks D, Mokbel N, Coles CA, White JD, Turner N, Daly RJ, Cooney GJ. Ablation of Grb10 Specifically in Muscle Impacts Muscle Size and Glucose Metabolism in Mice. *Endocrinology* 2018; **159**: 1339-1351 [PMID: 29370381 DOI: 10.1210/en.2017-00851]
- 19 **Zarzour A**, Kim HW, Weintraub NL. Understanding Obesity-Related Cardiovascular Disease: It's All About Balance. *Circulation* 2018; **138**: 64-66 [PMID: 29967231 DOI: 10.1161/CIRCULATIONAHA.118.034454]
- 20 **Wang L**, Balas B, Christ-Roberts CY, Kim RY, Ramos FJ, Kikani CK, Li C, Deng C, Reyna S, Musi N, Dong LQ, DeFronzo RA, Liu F. Peripheral disruption of the Grb10 gene enhances insulin signaling and sensitivity in vivo. *Mol Cell Biol* 2007; **27**: 6497-6505 [PMID: 17620412 DOI: 10.1128/mcb.00679-07]
- 21 **Torgerson JS**, Hauptman J, Boldrin MN, Sjöström L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. *Diabetes Care* 2004; **27**: 155-161 [PMID: 14693982 DOI: 10.2337/diacare.27.1.155]
- 22 **Powell EE**, Wong VW, Rinella M. Non-alcoholic fatty liver disease. *Lancet* 2021; **397**: 2212-2224 [PMID: 33894145 DOI: 10.1016/S0140-6736(20)32511-3]
- 23 **Hajer GR**, van Haften TW, Visseren FL. Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. *Eur Heart J* 2008; **29**: 2959-2971 [PMID: 18775919 DOI: 10.1093/eurheartj/ehn387]
- 24 **Ormazabal V**, Nair S, Elfeky O, Aguayo C, Salomon C, Zuñiga FA. Association between insulin resistance and the development of cardiovascular disease. *Cardiovasc Diabetol* 2018; **17**: 122 [PMID: 30170598 DOI: 10.1186/s12933-018-0762-4]
- 25 **Trayhurn P**, Wood IS. Signalling role of adipose tissue: adipokines and inflammation in obesity. *Biochem Soc Trans* 2005; **33**: 1078-1081 [PMID: 16246049 DOI: 10.1042/BST0331078]
- 26 **Rosenson RS**. Clinical role of LDL and HDL subclasses and apolipoprotein measurement. *ACC Curr J Rev* 2004; **13**: 33-37
- 27 **Desbuquois B**, Carré N, Burnol AF. Regulation of insulin and type 1 insulin-like growth factor signaling and action by the Grb10/14 and SH2B1/B2 adaptor proteins. *FEBS J* 2013; **280**: 794-816 [PMID: 23190452 DOI: 10.1111/febs.12080]
- 28 **Luo L**, Jiang W, Liu H, Bu J, Tang P, Du C, Xu Z, Luo H, Liu B, Xiao B, Zhou Z, Liu F. De-silencing *Grb10* contributes to acute ER stress-induced steatosis in mouse liver. *J Mol Endocrinol* 2018; **60**: 285-297 [PMID: 29555819 DOI: 10.1530/JME-18-0018]
- 29 **Madon-Simon M**, Cowley M, Garfield AS, Moorwood K, Bauer SR, Ward A. Antagonistic roles in fetal development and adult physiology for the oppositely imprinted *Grb10* and *Dlk1* genes. *BMC Biol* 2014; **12**: 771 [PMID: 25551289 DOI: 10.1186/s12915-014-0099-8]
- 30 **Liu M**, Bai J, He S, Villarreal R, Hu D, Zhang C, Yang X, Liang H, Slaga TJ, Yu Y, Zhou Z, Blenis J, Scherer PE, Dong LQ, Liu F. Grb10 promotes lipolysis and thermogenesis by phosphorylation-dependent feedback inhibition of mTORC1. *Cell Metab* 2014; **19**: 967-980 [PMID: 24746805 DOI: 10.1016/j.cmet.2014.03.018]
- 31 **Yea SS**, Fruman DA. Cell signaling. New mTOR targets Grb attention. *Science* 2011; **332**: 1270-1271 [PMID: 21659593 DOI: 10.1126/science.1208071]
- 32 **Cai Z**, Liu F, Yang Y, Li D, Hu S, Song L, Yu S, Li T, Liu B, Luo H, Zhang W, Zhou Z, Zhang J. GRB10 regulates β -cell mass by inhibiting β -cell proliferation and stimulating β -cell dedifferentiation. *J Genet Genomics* 2022; **49**: 208-216 [PMID: 34861413 DOI: 10.1016/j.jgg.2021.11.006]
- 33 **Khamzina L**, Veilleux A, Bergeron S, Marette A. Increased activation of the mammalian target of rapamycin pathway in liver and skeletal muscle of obese rats: possible involvement in obesity-linked insulin resistance. *Endocrinology* 2005; **146**: 1473-1481 [PMID: 15604215 DOI: 10.1210/en.2004-0921]
- 34 **Chakrabarti P**, English T, Shi J, Smas CM, Kandror KV. Mammalian target of rapamycin complex 1 suppresses lipolysis, stimulates lipogenesis, and promotes fat storage. *Diabetes* 2010; **59**: 775-781 [PMID: 20068142 DOI: 10.2337/db09-1602]
- 35 **Polak P**, Cybulski N, Feige JN, Auwerx J, Rügge MA, Hall MN. Adipose-specific knockout of raptor results in lean mice with enhanced mitochondrial respiration. *Cell Metab* 2008; **8**: 399-410 [PMID: 19046571 DOI: 10.1016/j.cmet.2008.09.003]
- 36 **Soliman GA**. The integral role of mTOR in lipid metabolism. *Cell Cycle* 2011; **10**: 861-862 [PMID: 21325894 DOI: 10.4161/cc.10.6.14930]



Published by **Baishideng Publishing Group Inc**
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-3991568
E-mail: bpgoffice@wjgnet.com
Help Desk: <https://www.f6publishing.com/helpdesk>
<https://www.wjgnet.com>

